Andrew Parsonson, Medical Oncologist, Macquarie University Clinical Associates, shared a post on X:
“DB-1311 (B7-H3 Target ADC with TOP1i payload) uORR 56% in SCLC and encouraging activity and safety in multiple tumours (NSCLC, CRPC, HCC, HNSCC, CC, Melanoma) Dose expansion recruitment ongoing.”
Christina Teng, Medical Oncologist at Scientia Clinical Research Australia, shared this post on X, adding:
“This compound is going places!
Charlotte Lemech still recruiting Scientia Clinical Research Australia. Hope ESMOASIA2024 is a blast! Looking forward to Australian Rare Cancer Portal. GC, BTC, sarcoma, GBM results to come. Also great to see Australian oncologists coming on board and others in Australia.”
